Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

In vitro activity of imipenem-relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.

Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.

Int J Antimicrob Agents. 2019 Nov 5. pii: S0924-8579(19)30302-4. doi: 10.1016/j.ijantimicag.2019.10.022. [Epub ahead of print]

PMID:
31704217
2.

In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance United States 2015-2017.

Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2019 Nov 4. pii: S2213-7165(19)30290-5. doi: 10.1016/j.jgar.2019.10.028. [Epub ahead of print]

PMID:
31698105
3.

How Ambient Cues Facilitate Political Segregation.

Motyl M, Prims JP, Iyer R.

Pers Soc Psychol Bull. 2019 Oct 3:146167219875141. doi: 10.1177/0146167219875141. [Epub ahead of print]

PMID:
31578933
4.

Activity of Ceftolozane-Tazobactam and Comparators against Pseudomonas aeruginosa from Patients in Different Risk Strata -- SMART United States 2016-2017.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2019 Jul 24. pii: S2213-7165(19)30183-3. doi: 10.1016/j.jgar.2019.07.017. [Epub ahead of print]

PMID:
31351246
5.

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.

Young K, Painter RE, Raghoobar SL, Hairston NN, Racine F, Wisniewski D, Balibar CJ, Villafania A, Zhang R, Sahm DF, Blizzard T, Murgolo N, Hammond ML, Motyl MR.

BMC Microbiol. 2019 Jul 4;19(1):150. doi: 10.1186/s12866-019-1522-7.

6.

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.

Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.

Diagn Microbiol Infect Dis. 2019 Oct;95(2):212-215. doi: 10.1016/j.diagmicrobio.2019.05.001. Epub 2019 May 8.

PMID:
31174995
7.

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Gueny ME, Sahm DF.

J Antimicrob Chemother. 2019 Aug 1;74(8):2284-2288. doi: 10.1093/jac/dkz191.

PMID:
31086960
8.

Predicting Antibiotic Resistance in Gram-Negative Bacilli from Resistance Genes.

Walker GT, Quan J, Higgins SG, Toraskar N, Chang W, Saeed A, Sapiro V, Pitzer K, Whitfield N, Lopansri BK, Motyl M, Sahm D.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02462-18. doi: 10.1128/AAC.02462-18. Print 2019 Apr.

9.

Extremists on the Left and Right Use Angry, Negative Language.

Frimer JA, Brandt MJ, Melton Z, Motyl M.

Pers Soc Psychol Bull. 2019 Aug;45(8):1216-1231. doi: 10.1177/0146167218809705. Epub 2018 Dec 11.

PMID:
30537899
10.

Genomic characterization of IMP and VIM carbapenemase-encoding transferable plasmids of Enterobacteriaceae.

Matsumura Y, Peirano G, Bradford PA, Motyl MR, DeVinney R, Pitout JDD.

J Antimicrob Chemother. 2018 Nov 1;73(11):3034-3038. doi: 10.1093/jac/dky303.

PMID:
30099521
11.

Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.

Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:140-147. doi: 10.1016/j.jgar.2018.07.012. Epub 2018 Jul 30.

PMID:
30071354
12.

Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.

Taj-Aldeen SJ, Salah H, Perez WB, Almaslamani M, Motyl M, AbdulWahab A, Healey KR, Perlin DS.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00214-18. doi: 10.1128/AAC.00214-18. Print 2018 Sep.

13.

In Vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem-Cilastatin in Murine Infection Models.

Powles MA, Galgoci A, Misura A, Colwell L, Dingley KH, Tang W, Wu J, Blizzard T, Motyl M, Young K.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e02577-17. doi: 10.1128/AAC.02577-17. Print 2018 Aug.

14.

Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:12-19. doi: 10.1016/j.jgar.2018.05.017. Epub 2018 May 29.

PMID:
29857057
15.

Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008-2014.

Peirano G, Matsumura Y, Adams MD, Bradford P, Motyl M, Chen L, Kreiswirth BN, Pitout JDD.

Emerg Infect Dis. 2018 Jun;24(6):1010-1019. doi: 10.3201/eid2406.171648.

16.

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.

Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00169-18. doi: 10.1128/AAC.00169-18. Print 2018 Jul.

17.

Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1481-1489. doi: 10.1007/s10096-018-3274-y. Epub 2018 May 12.

PMID:
29754209
18.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.

J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879. doi: 10.1093/jac/dky107.

PMID:
29659861
19.

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.

Wu J, Racine F, Wismer MK, Young K, Carr DM, Xiao JC, Katwaru R, Si Q, Harradine P, Motyl M, Bhagunde PR, Rizk ML.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02323-17. doi: 10.1128/AAC.02323-17. Print 2018 May.

20.

Strong scientific theorizing is needed to improve replicability in psychological science.

Carsel T, Demos AP, Motyl M.

Behav Brain Sci. 2018 Jan;41:e123. doi: 10.1017/S0140525X1800078X.

PMID:
31064576
21.

Segregation and belief polarization as boundary conditions for when fusion leads to self-sacrifice.

Melton ZJ, Motyl M.

Behav Brain Sci. 2018 Jan;41:e211. doi: 10.1017/S0140525X1800170X.

PMID:
31064569
22.

Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli.

Stoesser N, Sheppard AE, Peirano G, Anson LW, Pankhurst L, Sebra R, Phan HTT, Kasarskis A, Mathers AJ, Peto TEA, Bradford P, Motyl MR, Walker AS, Crook DW, Pitout JD.

Sci Rep. 2017 Jul 19;7(1):5917. doi: 10.1038/s41598-017-06256-2.

23.

Genomic epidemiology of global VIM-producing Enterobacteriaceae.

Matsumura Y, Peirano G, Devinney R, Bradford PA, Motyl MR, Adams MD, Chen L, Kreiswirth B, Pitout JDD.

J Antimicrob Chemother. 2017 Aug 1;72(8):2249-2258. doi: 10.1093/jac/dkx148.

24.

The state of social and personality science: Rotten to the core, not so bad, getting better, or getting worse?

Motyl M, Demos AP, Carsel TS, Hanson BE, Melton ZJ, Mueller AB, Prims JP, Sun J, Washburn AN, Wong KM, Yantis C, Skitka LJ.

J Pers Soc Psychol. 2017 Jul;113(1):34-58. doi: 10.1037/pspa0000084. Epub 2017 Apr 27.

PMID:
28447837
25.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02209-16. doi: 10.1128/AAC.02209-16. Print 2017 Jun.

26.

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014.

Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, Sahm DF.

J Clin Microbiol. 2017 Jun;55(6):1638-1649. doi: 10.1128/JCM.02316-16. Epub 2017 Mar 15.

27.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.

PMID:
28291628
28.

Social and economic ideologies differentially predict prejudice across the political spectrum, but social issues are most divisive.

Crawford JT, Brandt MJ, Inbar Y, Chambers JR, Motyl M.

J Pers Soc Psychol. 2017 Mar;112(3):383-412. doi: 10.1037/pspa0000074.

PMID:
28221092
29.

Global Molecular Epidemiology of IMP-Producing Enterobacteriaceae.

Matsumura Y, Peirano G, Motyl MR, Adams MD, Chen L, Kreiswirth B, DeVinney R, Pitout JD.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02729-16. doi: 10.1128/AAC.02729-16. Print 2017 Apr.

30.

Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene.

Matsumura Y, Pitout JD, Gomi R, Matsuda T, Noguchi T, Yamamoto M, Peirano G, DeVinney R, Bradford PA, Motyl MR, Tanaka M, Nagao M, Takakura S, Ichiyama S.

Emerg Infect Dis. 2016 Nov;22(11):1900-1907. doi: 10.3201/eid2211.160519.

31.

Data from a pre-publication independent replication initiative examining ten moral judgement effects.

Tierney W, Schweinsberg M, Jordan J, Kennedy DM, Qureshi I, Sommer SA, Thornley N, Madan N, Vianello M, Awtrey E, Zhu LL, Diermeier D, Heinze JE, Srinivasan M, Tannenbaum D, Bivolaru E, Dana J, Davis-Stober CP, du Plessis C, Gronau QF, Hafenbrack AC, Liao EY, Ly A, Marsman M, Murase T, Schaerer M, Tworek CM, Wagenmakers EJ, Wong L, Anderson T, Bauman CW, Bedwell WL, Brescoll V, Canavan A, Chandler JJ, Cheries E, Cheryan S, Cheung F, Cimpian A, Clark MA, Cordon D, Cushman F, Ditto PH, Amell A, Frick SE, Gamez-Djokic M, Grady RH, Graham J, Gu J, Hahn A, Hanson BE, Hartwich NJ, Hein K, Inbar Y, Jiang L, Kellogg T, Legate N, Luoma TP, Maibeucher H, Meindl P, Miles J, Mislin A, Molden DC, Motyl M, Newman G, Ngo HH, Packham H, Ramsay PS, Ray JL, Sackett AM, Sellier AL, Sokolova T, Sowden W, Storage D, Sun X, Van Bavel JJ, Washburn AN, Wei C, Wetter E, Wilson CT, Darroux SC, Uhlmann EL.

Sci Data. 2016 Oct 11;3:160082. doi: 10.1038/sdata.2016.82.

32.

Complete Sequencing of Plasmids Containing blaOXA-163 and blaOXA-48 in Escherichia coli Sequence Type 131.

Stoesser N, Sheppard AE, Peirano G, Sebra R, Lynch T, Anson L, Kasarskis A, Motyl MR, Crook DW, Pitout JD.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6948-6951. doi: 10.1128/AAC.01130-16. Print 2016 Nov.

33.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
34.

Erratum to: In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study.

Biedenbach DJ, Badal RE, Huang MY, Motyl M, Singhal PK, Kozlov RS, Roman AD, Marcella S.

Infect Dis Ther. 2016 Sep;5(3):405. doi: 10.1007/s40121-016-0120-3. No abstract available.

35.

In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study.

Biedenbach DJ, Badal RE, Huang MY, Motyl M, Singhal PK, Kozlov RS, Roman AD, Marcella S.

Infect Dis Ther. 2016 Jun;5(2):139-53. doi: 10.1007/s40121-016-0112-3. Epub 2016 Jun 10. Erratum in: Infect Dis Ther. 2016 Sep;5(3):405.

36.

First Report of blaIMP-14 on a Plasmid Harboring Multiple Drug Resistance Genes in Escherichia coli Sequence Type 131.

Stoesser N, Sheppard AE, Peirano G, Sebra RP, Lynch T, Anson LW, Kasarskis A, Motyl MR, Crook DW, Pitout JD.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5068-71. doi: 10.1128/AAC.00840-16. Print 2016 Aug.

37.

Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013).

Zalacain M, Biedenbach DJ, Badal RE, Young K, Motyl M, Sahm DF.

Clin Ther. 2016 Jun;38(6):1510-1521. doi: 10.1016/j.clinthera.2016.04.035. Epub 2016 May 24.

PMID:
27234360
38.

Diverse crowds using diverse methods improves the scientific dialectic.

Motyl M, Iyer R.

Behav Brain Sci. 2015;38:e151. doi: 10.1017/S0140525X14001265.

PMID:
26786958
39.

Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin.

Apgar JM, Wilkening RR, Greenlee ML, Balkovec JM, Flattery AM, Abruzzo GK, Galgoci AM, Giacobbe RA, Gill CJ, Hsu MJ, Liberator P, Misura AS, Motyl M, Nielsen Kahn J, Powles M, Racine F, Dragovic J, Habulihaz B, Fan W, Kirwan R, Lee S, Liu H, Mamai A, Nelson K, Peel M.

Bioorg Med Chem Lett. 2015 Dec 15;25(24):5813-8. doi: 10.1016/j.bmcl.2015.10.011. Epub 2015 Oct 9.

PMID:
26542966
40.

Defining the happiness gap—Response.

Wojcik SP, Hovasapian A, Graham J, Motyl M, Ditto PH.

Science. 2015 Jun 12;348(6240):1216. doi: 10.1126/science.348.6240.1216-b. No abstract available.

PMID:
26068839
41.

Conservatives report, but liberals display, greater happiness.

Wojcik SP, Hovasapian A, Graham J, Motyl M, Ditto PH.

Science. 2015 Mar 13;347(6227):1243-6. doi: 10.1126/science.1260817.

42.

Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.

Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW.

Antimicrob Agents Chemother. 2015 Feb;59(2):790-5. doi: 10.1128/AAC.03706-14. Epub 2014 Nov 17.

43.

Will the real fundamental difference underlying ideology please stand up?

Motyl M, Iyer R.

Behav Brain Sci. 2014 Jun;37(3):322-3. doi: 10.1017/S0140525X13002677.

PMID:
24970445
44.

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS.

Antimicrob Agents Chemother. 2014;58(2):1248-51. doi: 10.1128/AAC.02145-13. Epub 2013 Dec 9.

45.

What is freedom--and does wealth cause it?

Iyer R, Motyl M, Graham J.

Behav Brain Sci. 2013 Oct;36(5):492-3; discussion 503-21. doi: 10.1017/S0140525X13000149. Epub 2013 Aug 29.

PMID:
23985337
46.

Synthesis and antifungal evaluation of pentyloxyl-diphenylisoxazoloyl pneumocandins and echinocandins.

Singh SB, Herath K, Kahn JN, Mann P, Abruzzo G, Motyl M.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3253-6. doi: 10.1016/j.bmcl.2013.03.115. Epub 2013 Apr 10.

PMID:
23623416
47.

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2013 Feb;57(2):1065-8. doi: 10.1128/AAC.01588-12. Epub 2012 Dec 10.

48.

Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).

Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M.

J Antimicrob Chemother. 2013 Apr;68(4):858-63. doi: 10.1093/jac/dks466. Epub 2012 Nov 28.

PMID:
23190764
49.

Scientific Utopia: II. Restructuring Incentives and Practices to Promote Truth Over Publishability.

Nosek BA, Spies JR, Motyl M.

Perspect Psychol Sci. 2012 Nov;7(6):615-31. doi: 10.1177/1745691612459058.

PMID:
26168121
50.

Creatureliness priming reduces aggression and support for war.

Motyl M, Hart J, Cooper DP, Heflick N, Goldenberg J, Pyszczynski T.

Br J Soc Psychol. 2013 Dec;52(4):648-66. doi: 10.1111/j.2044-8309.2012.02115.x. Epub 2012 Aug 13.

PMID:
22882271

Supplemental Content

Support Center